Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00589602 | T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases | terminated | Phase 2 | 13 | The Cleveland ClinicOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT02259348 | Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation | terminated | Phase 2 | 12 | St. Jude Children's Research HospitalOTHER | 1 | May 30, 2017 |
| clinicaltrials |
| NCT00088881 | Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma | terminated | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | May 25, 2017 | clinicaltrials |
| NCT00082017 | UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | May 15, 2017 | clinicaltrials |
| NCT01282476 | Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma | terminated | Phase 2 | 18 | Massachusetts General HospitalOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01889797 | Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma(PrE0401) | terminated | Phase 2 | 32 | PrECOG, LLC.OTHER | 1 | May 5, 2017 | clinicaltrials |
| NCT00681044 | HD Melphalan and SCT in Patients With IGDD or LCDD | terminated | Phase 2 | 5 | Boston Medical CenterOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00109889 | S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma | terminated | Phase 2 | 2 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 24, 2017 | clinicaltrials |
| NCT01173679 | Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL | terminated | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Apr 14, 2017 | clinicaltrials |
| NCT00596336 | Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients(CLLIFVAC) | terminated | Phase 2 | 24 | The Royal Bournemouth HospitalOTHER | 1 | Apr 12, 2017 | clinicaltrials |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | terminated | Phase 2 | 36 | Celldex TherapeuticsINDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT02227108 | Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma | terminated | Phase 2 | 37 | MedImmune LLCINDUSTRY | 8 | Apr 6, 2017 | clinicaltrials |
| NCT00360776 | Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2017 | clinicaltrials |
| NCT01534143 | High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant | terminated | Phase 2 | 1 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT00698685 | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation | terminated | Phase 2 | 14 | University of ArizonaOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT00490490 | Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy | terminated | Phase 2 | 8 | Stanford UniversityOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01118013 | Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant | terminated | Phase 2 | 6 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 24, 2017 | clinicaltrials |
| NCT01207765 | Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma | terminated | Phase 2 | 8 | Tufts Medical CenterOTHER | 1 | Mar 20, 2017 | clinicaltrials |
| NCT02670317 | Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.(FIL-GALILEO) | terminated | Phase 2 | 1 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Mar 20, 2017 | clinicaltrials |
| NCT01484314 | Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma | terminated | Phase 2 | 1 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01944943 | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia(VISMOLY) | terminated | Phase 2 | 31 | The Lymphoma Academic Research OrganisationOTHER | 1 | Mar 13, 2017 | clinicaltrials |
| NCT01621477 | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | terminated | Phase 2 | 34 | St. Jude Children's Research HospitalOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT02254551 | Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 7 | SCRI Development Innovations, LLCOTHER | 1 | Feb 16, 2017 | clinicaltrials |
| NCT02113007 | Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma | terminated | Phase 2 | 2 | SCRI Development Innovations, LLCOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01389076 | Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma | terminated | Phase 2 | 22 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT00075608 | 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis | terminated | Phase 2 | 12 | Boston Medical CenterOTHER | 1 | Jan 27, 2017 | clinicaltrials |
| NCT01485536 | A Study of the HSP90 Inhibitor AUY922 | terminated | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT01695330 | Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens | terminated | Phase 2 | 5 | OncotherapeuticsINDUSTRY | 1 | Jan 16, 2017 | clinicaltrials |
| NCT02129062 | Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2017 | clinicaltrials |
| NCT01637090 | Everolimus in Treating Cutaneous T-cell Lymphoma(CTCL) | terminated | Phase 2 | 3 | Adam LernerOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT02439138 | Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia | terminated | Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT02086591 | A Phase II Study of Doxycycline in Relapsed NHL | terminated | Phase 2 | 7 | University of RochesterOTHER | 1 | Dec 22, 2016 | clinicaltrials |
| NCT01944982 | Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma(HNJ-NKAES-2012) | terminated | Phase 1 / Phase 2 | 7 | Hospital Infantil Universitario Niño Jesús, Madrid, SpainOTHER | 1 | Dec 20, 2016 | clinicaltrials |
| NCT01600053 | Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia | terminated | Phase 2 | 11 | Thomas KippsOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT01401322 | Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia | terminated | Phase 2 | 5 | Stanford UniversityOTHER | 1 | Nov 28, 2016 | clinicaltrials |
| NCT00978432 | Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | terminated | Phase 2 | 50 | Anne Beaven, MDOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02020941 | Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy | terminated | Phase 2 | 10 | Attaya SuvannasankhaOTHER | 1 | Nov 2, 2016 | clinicaltrials |
| NCT00098371 | Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia | terminated | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Oct 24, 2016 | clinicaltrials |
| NCT01186458 | Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma | terminated | Phase 2 | 4 | Hoosier Cancer Research NetworkOTHER | 1 | Oct 24, 2016 | clinicaltrials |
| NCT01144403 | A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma. | terminated | Phase 2 | 8 | Hoffmann-La RocheINDUSTRY | 1 | Oct 18, 2016 | clinicaltrials |
| NCT01699581 | Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant | terminated | Phase 2 | 35 | Greg MonohanOTHER | 1 | Oct 18, 2016 | clinicaltrials |
| NCT00788606 | R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma | terminated | Phase 2 | 7 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT00278265 | Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia | terminated | Phase 2 | 12 | German CLL Study GroupOTHER | 1 | Oct 3, 2016 | clinicaltrials |
| NCT00281931 | Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia | terminated | Phase 2 | 21 | German CLL Study GroupOTHER | 1 | Sep 26, 2016 | clinicaltrials |
| NCT02573935 | Clarithromycin in Multiple Myeloma Induction Therapy(CLAIM) | terminated | Phase 2 | 58 | Henrik GregersenOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT01121757 | Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma | terminated | Phase 2 | 11 | Duke UniversityOTHER | 1 | Sep 12, 2016 | clinicaltrials |
| NCT00984828 | Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients | terminated | Phase 2 / Phase 3 | 23 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 8, 2016 | clinicaltrials |
| NCT02808091 | Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma(Gifox-B) | terminated | Phase 2 | 7 | National Cancer Centre, SingaporeOTHER | 1 | Sep 5, 2016 | clinicaltrials |
| NCT00771056 | Hydroxychloroquine in Untreated B-CLL Patients | terminated | Phase 2 | 23 | Northwell HealthOTHER | 1 | Aug 22, 2016 | clinicaltrials |
Data updated 23 days agoSource updated May 30, 2017source: clinicaltrials